

Pulmonary *FABP4* is an inverse biomarker of pneumonia in critically ill children and adults

*Emily C. Lydon¹, *Hoang Van Phan¹, Eran Mick^{1,2,3}, Natasha Spottiswoode¹, Carolyn S. Calfee³, Peter M. Mourani⁴, Charles R. Langelier^{1,2}

*equal contributions

¹Division of Infectious Diseases, University of California, San Francisco, CA, USA

²Chan Zuckerberg Biohub San Francisco, San Francisco, CA, USA

³Division of Pulmonary and Critical Care Medicine, Cardiovascular Research Institute, University of California, San Francisco, CA, USA

⁴Department of Pediatrics, Section of Critical Care, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, AR, USA

Corresponding Author:

Emily C. Lydon

513 Parnassus Avenue, Room S380

San Francisco, CA 94143

Contributions:

CSC, PMM, CRL secured funding and designed and enrolled the clinical cohorts. ECL, CRL, PMM, CSC, and NS performed clinical adjudications for the cohorts. CRL performed RNA extractions and sequencing. EM, HVP, CRL, NS, and ECL conceived this specific project idea. HVP and EM performed data analysis and generated the figure. ECL, HVP, and CRL wrote the initial draft of the manuscript. All authors reviewed and approved the final manuscript.

Funding:

5R01HL155418 (CRL, PMM); Chan Zuckerberg Biohub San Francisco (CRL); R35HL140026 (CSC); R01HL124103 (PMM)

Abstract

Lower respiratory tract infection (LRTI) is a leading cause of mortality, yet accurate diagnosis remains challenging. We studied two prospective observational cohorts of critically ill patients with acute respiratory failure (pediatric, N=261; adult N=202) and analyzed RNA sequencing data from tracheal aspirate collected following intubation. Patients with LRTI or non-infectious acute respiratory failure were adjudicated by a multi-physician team. We found that *FABP4* expression was significantly downregulated in children with confirmed LRTI compared to those with non-infectious respiratory failure, and when incorporated into a diagnostic classifier, achieved an area under the receiver operating characteristic curve (AUC) of 0.90 ± 0.07 . When tested in the adult cohort, and AUC of 0.85 ± 0.12 was attained. These findings suggest that pulmonary *FABP4* could serve as a valuable biomarker for the early diagnosis of LRTI in critically ill patients across the age spectrum, offering a potential tool for improving clinical outcomes and reducing unnecessary antibiotic use.

2 Manuscript

3 Lower respiratory tract infection (LRTI) is a leading cause of death worldwide, yet
4 the diagnosis is often challenging since non-infectious respiratory processes can present
5 similarly. Furthermore, existing culture-based microbiologic testing is time-consuming,
6 can return falsely negative with preceding antibiotics, and may identify microbes unrelated
7 to a pulmonary infection. Consequently, clinicians often turn to rapid host response-based
8 peripheral blood biomarkers, such as procalcitonin and C-reactive protein (CRP), for
9 gauging LRTI suspicion and deciding to initiate empiric antibiotics. Procalcitonin has
10 some utility in distinguishing bacterial and viral etiologies of LRTI, but diagnostic
11 performance is limited in critically ill patients, and CRP performs worse.(1,2) Presently,
12 no clinically available host biomarkers accurately distinguish all-cause LRTI from non-
13 infectious respiratory illness.

14 To address the need for better LRTI diagnostics, we previously utilized respiratory
15 metatranscriptomics to build multi-gene host classifiers that accurately differentiate LRTI
16 from non-infectious acute respiratory syndromes in critically ill adults and children. These
17 classifiers achieved remarkable accuracy, both when used on their own and when
18 integrated with microbial detection.(3,4) While promising, the practical complexities of
19 RNA sequencing precludes immediate implementation in many clinical settings. We
20 therefore sought to identify whether a single gene could accurately diagnose LRTI in
21 patients with acute respiratory failure.

22 We first evaluated a recently described(4) prospective multicenter cohort of 261
23 critically ill children with acute respiratory failure (Table 1). Transcriptional profiling was
24 performed on tracheal aspirate (TA) samples collected <24 hours after intubation using

25 previously described methods.(4) Retrospective clinical adjudication classified subjects
26 into four LRTI groups: Definite (clinical LRTI diagnosis with compatible microbiology,
27 n=117), Suspected (clinical LRTI diagnosis with negative microbiology, n=57),
28 Indeterminate (clinical uncertainty regarding LRTI, n=37), and No Evidence (clear non-
29 infectious etiology with negative microbiology, n=50). Most Definite LRTI cases were viral,
30 reflecting the typical microbiology of pediatric community-acquired LRTI.(5) Etiologies of
31 non-infectious respiratory failure included seizures, trauma, airway abnormalities, and
32 ingestion. Differential gene expression analysis between Definite and No Evidence
33 subjects identified 4,718 genes at a Benjamini-Hochberg adjusted p-value (P_{adj})<0.05,
34 with the gene fatty acid-binding protein 4 (*FABP4*) emerging as the most promising
35 candidate biomarker (P_{adj} <0.0001) (Figure 1A). Five-fold cross-validation on normalized
36 *FABP4* gene expression in the Definite and No Evidence groups yielded an area under
37 the receiver operator curve (AUC) of 0.90 ± 0.07 for diagnosing LRTI, equating to a
38 sensitivity of $86\pm 7\%$ and specificity of $90\pm 7\%$ at Youden's index (Figure 1B). *FABP4*
39 classified 73.7% of the Suspected group and 54.1% of the Indeterminate group as LRTI,
40 aligning with stronger suspicion of LRTI in the former.

41 Given that LRTI microbiology and immune responses vary with age, it was
42 uncertain whether *FABP4* would perform as well in diagnosing adult LRTI. We therefore
43 assessed *FABP4* expression in an independent prospective cohort of 202 adults requiring
44 intubation for acute respiratory failure (Table 1).(3) A similar retrospective clinical LRTI
45 adjudication approach identified 44 Definite, 36 Suspected, 66 Indeterminate, and 56 No
46 Evidence subjects. In contrast to the pediatric cohort, the adult Definite subjects had
47 predominantly bacterial LRTI and included subjects with both hospital-acquired and

48 community-acquired pneumonia. Etiologies of non-infectious respiratory failure included
49 cardiac disease, neurologic syndromes, and primary pulmonary processes (e.g., COPD,
50 ILD, pulmonary embolism). Utilizing transcriptional profiling of TA samples collected <72
51 hours after intubation, we compared *FABP4* gene expression across LRTI status. *FABP4*
52 exhibited a similarly striking decrease in expression in adults with Definite LRTI compared
53 to No Evidence ($P_{\text{adj}} < 0.0001$) and achieved an AUC of 0.85 ± 0.12 when used as a
54 diagnostic classifier in these two groups (Figure 1). Similar to the pediatric cohort, *FABP4*
55 predicted LRTI in 66.7% of the Suspected group and 31.8% of the Indeterminate group.

56 So what is *FABP4*, and why might it be downregulated in LRTI? Fatty-acid binding
57 proteins are a family of intracellular proteins that regulate fatty acid trafficking and
58 signaling.(6) In the lung, *FABP4* is considered a marker of tissue-resident alveolar
59 macrophages, and severe SARS-CoV-2 infection has recently been shown to drastically
60 deplete the *FABP4*-expressing alveolar macrophage population.(7,8) Prior studies have
61 also linked increased *FABP4* levels to non-infectious chronic pulmonary conditions
62 including bronchopulmonary dysplasia, sarcoidosis, and asthma.(6) The precise
63 mechanism for *FABP4* downregulation in infection – or, alternatively, upregulation in non-
64 infectious lung disease – remains unclear. From a diagnostic lens, a study of ventilator-
65 associated pneumonia identified *FABP4* as one of the most downregulated proteins in
66 TA, and a study of COPD patients noted decreased sputum *FABP4* protein levels in
67 bacterial infection, supporting our transcriptomic findings at the protein level.(9,10)

68 Taken together, these results demonstrate that *FABP4* is a promising age-agnostic,
69 inverse-biomarker for all-cause LRTI in two independent cohorts of critically ill, intubated
70 patients. *FABP4* achieved high accuracy for LRTI diagnosis in both cohorts, with

71 performance exceeding those of existing clinical biomarkers(1,2) despite differing ages,
72 microbiology, comorbidity burden, and preceding healthcare exposures. As host immune
73 responses are more dynamic and informative at the site of infection, the identification of
74 an accurate LRTI biomarker from respiratory fluid rather than peripheral blood, while
75 novel, is perhaps not surprising. Diagnostically, *FABP4* could add value to standard TA
76 culture, both in discriminating LRTI pathogens from colonizing microbes and in
77 diagnosing LRTI when cultures are hindered by preceding antibiotics. In addition to
78 improving LRTI diagnosis for the individual patient, a pan-pathogen host biomarker of
79 LRTI could have utility for pandemic preparedness and infection control, enabling rapid
80 screening, early isolation, and other prevention measures.

81 These preliminary findings require independent validation in additional cohorts with
82 both transcriptomic and proteomic approaches. It remains unknown whether *FABP4* has
83 diagnostic utility in non-critically ill patients, or when measured in more broadly accessible
84 sample types, such as sputum, nasal swabs, or blood. To better understand the
85 mechanism of *FABP4* modulation and to gauge whether particular cell types may mediate
86 or confound *FABP4* expression, cytometry and single-cell RNA sequencing on lower
87 respiratory tract samples from patients with LRTI, non-infectious respiratory syndromes,
88 and healthy controls will be valuable. Lastly, an important step towards clinical translation
89 will be development of RT-qPCR and/or lateral-flow protein assays. In sum, we find that
90 pulmonary *FABP4* is a novel, downregulated biomarker of severe LRTI across the age
91 spectrum, with promising utility in critically ill patients.

92 **References**

- 93 1. Self WH, Balk RA, Grijalva CG, Williams DJ, Zhu Y, Anderson EJ, *et al.* Procalcitonin
94 as a Marker of Etiology in Adults Hospitalized With Community-Acquired Pneumonia.
95 *Clin Infect Dis* 2017;65:183–190.
- 96 2. van der Meer V, Neven AK, van den Broek PJ, Assendelft WJJ. Diagnostic value of C
97 reactive protein in infections of the lower respiratory tract: systematic review. *BMJ*
98 2005;331:26.
- 99 3. Langelier C, Kalantar KL, Moazed F, Wilson MR, Crawford ED, Deiss T, *et al.*
100 Integrating host response and unbiased microbe detection for lower respiratory tract
101 infection diagnosis in critically ill adults. *Proc Natl Acad Sci U S A* 2018;115:E12353–
102 E12362.
- 103 4. Mick E, Tsitsiklis A, Kamm J, Kalantar KL, Caldera S, Lyden A, *et al.* Integrated
104 host/microbe metagenomics enables accurate lower respiratory tract infection diagnosis
105 in critically ill children. *J Clin Invest* 2023;133:
- 106 5. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, *et al.* Community-
107 Acquired Pneumonia Requiring Hospitalization among U.S. Children. *New England*
108 *Journal of Medicine* 2015;372:835–845.
- 109 6. Furuhashi M, Saitoh S, Shimamoto K, Miura T. Fatty Acid-Binding Protein 4 (FABP4):
110 Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and
111 Cardiovascular Diseases. *Clin Med Insights Cardiol* 2014;8s3:CMC.S17067.
- 112 7. Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, *et al.* Single-cell landscape of
113 bronchoalveolar immune cells in patients with COVID-19. *Nat Med* 2020;26:842–844.

- 114 8. Chen ST, Park MD, Del Valle DM, Buckup M, Tabachnikova A, Thompson RC, *et al.*
115 A shift in lung macrophage composition is associated with COVID-19 severity and
116 recovery. *Science Translational Medicine* 2022;14:eabn5168.
- 117 9. Pathak KV, McGilvrey MI, Hu CK, Garcia-Mansfield K, Lewandoski K, Eftekhari Z, *et*
118 *al.* Molecular Profiling of Innate Immune Response Mechanisms in Ventilator-associated
119 Pneumonia. *Mol Cell Proteomics* 2020;19:1688–1705.
- 120 10. Perea L, Rodrigo-Troyano A, Cantó E, Domínguez-Álvarez M, Giner J, Sanchez-
121 Reus F, *et al.* Reduced airway levels of fatty-acid binding protein 4 in COPD:
122 relationship with airway infection and disease severity. *Respir Res* 2020;21:21.

123

124

125 **Data and Code Availability**

126 All data, code, and results are available at: [https://github.com/infectiousdisease-langelier-](https://github.com/infectiousdisease-langelier-lab/LRTI_FABP4_classifier)
127 [lab/LRTI_FABP4_classifier](https://github.com/infectiousdisease-langelier-lab/LRTI_FABP4_classifier) for reviewing and reproducing the analyses.

128

129 **Ethics Statement**

130 The pediatric cohort study was approved by the Collaborative Pediatric Critical Care
131 Research IRB at the University of Utah (protocol #00088656). Informed consent was
132 obtained from parents or other legal guardians. The adult cohort was approved by the
133 University of California Institutional Review Board (protocol #10-02701) and informed
134 consent was obtained from patients or surrogate decision makers.

Tables

Pediatric Cohort (n=261)					
	LRTI (n=117)	No LRTI (n=50)	P value	Suspected (n=57)	Indeterminate (n=37)
Female, n (%)	45 (38.5%)	25 (50.0%)	0.18	26 (45.6%)	16 (43.2%)
Age, median (IQR)	0.5 (0.2–1.8)	6.5 (1.5–12.9)	<0.001*	1.7 (0.6-6.0)	1.5 (0.6-10.8)
Race			0.45		
White, n (%)	69 (59.0%)	30 (60.0%)		33 (57.9%)	20 (54.1%)
Black/African American, n (%)	26 (22.2%)	7 (14.0%)		11 (19.3%)	10 (27.0%)
Asian, n (%)	5 (4.3%)	6 (12.0%)		2 (3.5%)	2 (5.4%)
American Indian/Alaska Native, n (%)	1 (0.9%)	1 (2.0%)		1 (1.8%)	0 (0.0%)
Native Hawaiian/Pacific Islander, n (%)	1 (0.9%)	0 (0.0%)		0 (0.0%)	0 (0.0%)
Multi-racial, n (%)	3 (2.6%)	1 (2.0%)		1 (1.8%)	1 (2.7%)
Unknown/Other, n (%)	12 (10.3%)	5 (10.0%)		9 (15.8%)	4 (10.8%)
Hispanic/Latino, n (%)	17 (14.5%)	6 (12.0%)	0.81	14 (24.6%)	7 (18.9%)
Comorbidities, n (%)	38 (32.5%)	26 (52.0%)	0.02*	34 (59.7%)	14 (37.8%)
Immunosuppressed, n (%)	3 (2.6%)	7 (14.0%)	0.01*	5 (8.8%)	6 (16.2%)
Overweight/obese BMI, n (%)	30 (25.6%)	14 (28%)	0.84	17 (29.8%)	11 (29.7%)
Renal dysfunction, n (%)	5 (4.3%)	8 (16.0%)	0.02*	6 (10.5%)	8 (21.6%)
ARDS (Berlin Criteria), n (%)	30 (25.6%)	9 (18.0%)	0.32	23 (40.4%)	7 (18.9%)
Antibiotics on day of enrollment	112 (95.7%)	42 (84.0%)	0.02*	51 (89.5%)	30 (69.8%)
LRTI type					
Bacterial, n (%)	16 (13.6%)				
Viral, n (%)	54 (46.2%)				
Fungal, n (%)	0.0 (0.0%)				
Co-infection, n (%)	47 (40.2%)				

Table 1 (spans two pages; see caption below).

Adult Cohort (n=202)					
	LRTI (n=44)	No LRTI (n=56)	P value	Suspected (n=36)	Indeterminate (n=66)
Female, n (%)	14 (31.8%)	31 (55%)	0.03*	8 (22.2%)	28 (42.4%)
Age, median (IQR)	63.5 (47.0-75.5)	62.0 (52.0-70.0)	0.75	67.0 (59.5-74.5)	59 (47.0-70.0)
Race			0.94		
White, n (%)	23 (52.3%)	28 (50.0%)		20 (55.6%)	34 (51.5%)
Black/African American, n (%)	4 (9.1%)	5 (8.9%)		1 (2.8%)	4 (6.1%)
Asian, n (%)	8 (18.2%)	12 (21.4%)		12 (33.3%)	9 (13.6%)
American Indian/Alaska Native, n (%)	0 (0.0%)	0 (0.0%)		0 (0.0%)	1 (1.5%)
Native Hawaiian/Pacific Islander, n (%)	1 (2.2%)	0 (0.0%)		0 (0.0%)	2 (3.0%)
Multi-racial, n (%)	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)
Unknown/Other, n (%)	8 (18.2%)	11 (19.6%)		3 (8.3%)	16 (24.2%)
Hispanic/Latino, n (%)	6 (13.6%)	12 (21.4%)	0.43	5 (13.9%)	18 (27.3%)
Comorbidities, n (%)	43 (97.7%)	52 (92.9%)	0.38	36 (100.0%)	59 (89.4%)
Immunosuppressed, n (%)	10 (22.7%)	7 (12.5%)	0.19	3 (8.3%)	9 (13.6%)
Overweight/obese BMI, n (%)	23 (52.3%)	39 (69.6%)	0.10	17 (47.2%)	44 (66.7%)
Renal dysfunction, n (%)	23 (52.3%)	34 (60.7%)	0.42	22 (61.1%)	39 (59.1%)
ARDS (Berlin Criteria), n (%)	28 (63.6%)	8 (14.2%)	<0.001*	20 (55.6%)	25 (37.9%)
Antibiotics on day of enrollment	38 (86.4%)	45 (80.3%)	0.59	36 (100.0%)	58 (87.9%)
LRTI type					
Bacterial, n (%)	32 (72.7%)				
Viral, n (%)	6 (13.6%)				
Fungal, n (%)	1.0 (2.3%)				
Co-infection, n (%)	5 (11.4%)				

Table 1: Demographic and clinical characteristics of the pediatric and adult cohorts. Abnormal BMI was classified as $>25 \text{ kg/m}^2$ for adults and $>85^{\text{th}}$ percentile for children. Renal dysfunction was classified as creatinine above the upper limit of normal and/or need for renal replacement therapy while hospitalized. Mann-Whitney test was used for all continuous variables, and Fisher's exact test was used for all categorical values. Asterisk (*) indicates $p < 0.05$ between the Definite and No Evidence groups. ARDS, acute respiratory distress syndrome.




Figure 1: *FABP4* performance in adult and pediatric cohorts. (A) Volcano plot displaying differential expression of all genes quantified by RNA sequencing between Definite LRTI and No Evidence subjects within the pediatric cohort. $\log_2(\text{fold change})$ is plotted against $-\log_{10}(P_{\text{adj}})$ for each gene. Statistically significant genes ($P_{\text{adj}} < 0.05$) are shown in black and non-significant genes are shown in grey. *FABP4* gene is highlighted in orange as highly downregulated in LRTI patients. (B) Receiver operating characteristic (ROC) curve demonstrating *FABP4* performance in diagnosing LRTI in the pediatric (orange) and adult (green) cohorts. The faded lines indicate results from each of the 5-fold validations on normalized *FABP4* gene counts. The area under the curve (AUC) is presented as mean \pm standard deviation.